Puma Biotechnology (PBYI) Common Equity (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Common Equity came in at $128.4 million in Q1 2026, up 32.24% YoY from $97.1 million in Q1 2025, and down 1.48% on a QoQ basis from $130.3 million in Q4 2025.
Puma Biotechnology (PBYI) Common Equity (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Common Equity data on file, last reported at $128.4 million in Q1 2026.
- Quarterly Common Equity rose 32.24% year-over-year to $128.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.4 million (up 32.24% YoY) and the FY2025 annual result came in at $130.3 million, up 41.48% from the prior year.
- Common Equity retreated to $128.4 million in Q1 2026, from $130.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $130.3 million in Q4 2025 to a low of $7.1 million in Q1 2022.
- A 5-year average of $62.2 million and a median of $51.0 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 983.4% in 2022, down 56.26% in 2022.
- Tracing PBYI's Common Equity over 5 years: stood at $21.6 million in 2022, then soared by 147.33% to $53.4 million in 2023, then soared by 72.38% to $92.1 million in 2024, then soared by 41.48% to $130.3 million in 2025, then dropped by 1.48% to $128.4 million in 2026.
- The last three Common Equity figures came in at $128.4 million (Q1 2026), $130.3 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 138.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.54 Mn |
| Mar 31, 2026 | 128.42 Mn |
| Dec 31, 2025 | 130.34 Mn |
| Sep 30, 2025 | 115.27 Mn |
| Jun 30, 2025 | 104.72 Mn |
| Mar 31, 2025 | 97.11 Mn |
| Dec 31, 2024 | 92.13 Mn |
| Sep 30, 2024 | 71.09 Mn |
| Jun 30, 2024 | 48.51 Mn |
| Mar 31, 2024 | 50.98 Mn |
| Dec 31, 2023 | 53.44 Mn |
| Sep 30, 2023 | 38.74 Mn |
| Jun 30, 2023 | 30.40 Mn |
| Mar 31, 2023 | 25.85 Mn |
| Dec 31, 2022 | 21.61 Mn |
| Sep 30, 2022 | 22.16 Mn |
| Jun 30, 2022 | 19.74 Mn |
| Mar 31, 2022 | 7.15 Mn |
| Dec 31, 2021 | -2.45 Mn |
| Sep 30, 2021 | -10.92 Mn |